Vulvovaginal Atrophy (VVA)
When changes in vaginal tissue impact intimate well-being
Vulvovaginal atrophy is common among menopausal women1. It affects vaginal health and can significantly impact quality of life5.
The condition and its symptoms
What is Vulvovaginal Atrophy?
Vulvovaginal Atrophy is a condition that affects the female genital area. It is primarily associated with reduced oestrogen levels, most commonly during menopause, but may also occur in other hypo-oestrogenic states1.
Oestrogens are hormones that play several roles in the female body. They help maintain proper vaginal pH1, regulate vaginal blood flow1, support lubrication3, and keep vaginal tissue healthy and flexible3.
When oestrogen levels drop, symptoms like vaginal dryness and discomfort can develop1. Without appropriate management, symptoms may persist and can impact quality of life5.
Vaginal discomfort and pain2
Less elastic vaginal tissue4
Vaginal dryness3
Thinning and inflamed vaginal lining4
A consequence of menopause
Vulvovaginal atrophy, now commonly recognised as part of Genitourinary Syndrome of Menopause (GSM), is associated with reduced oestrogen levels, most often during menopause. Lower oestrogen can lead to changes in vaginal tissue, causing symptoms such as dryness, irritation, discomfort, and reduced elasticity, which may affect quality of life. Women experiencing symptoms should seek advice from a healthcare professional5.
Who is affected by Vulvovaginal Atrophy
Vulvovaginal atrophy can affect women in low-oestrogen states and is most common during menopause1.
Studies show that symptoms of vulvovaginal atrophy are common among postmenopausal women5.
Symptoms may also occur temporarily during periods of reduced oestrogen levels.
Some situations where oestrogen levels decrease temporarily:
After childbirth
During breastfeeding
While undergoing certain breast cancer treatments
When taking specific medications that affect hormone levels
How Vulvovaginal Atrophy develops
The decrease in oestrogen levels during menopause leads to both structural and functional changes in vaginal tissues.
Data about Vulvovaginal atrophy and Genitourinary syndrome of menopause
Vulvovaginal atrophy can have a significant impact on women’s intimate lives and overall well-being5.

65%
Report less sexual satisfaction2
The Revive (Real women’s views of treatment options for menopausal vaginal changes) survey of 3046 postmenopausal women with GSM.
62%
Say it affects their ability to be intimate2
The Revive (Real women’s views of treatment options for menopausal vaginal changes) survey of 3046 postmenopausal women with GSM showed VVA has negative impact on the ability to be intimate 62%.
55%
Say their relationship has suffered2
The Revive (Real women’s views of treatment options for menopausal vaginal changes) survey of 3046 postmenopausal women with GSM.
Diagnosing the disease
Professional medical evaluation is essential for diagnosing vaginal atrophy.
To diagnose the condition, the doctor will ask about your symptoms, their duration, and any related factors. Additional tests may be requested to rule out other conditions with similar manifestations.
A pelvic examination may also be performed to look for signs of atrophy, such as thinning of the vaginal epithelium, loss of rugal folds, and changes in mucosal colouration.


The art of feeling
Comprehensive care for intimate well-being
At IBSA, we approach uro-gynecological conditions with the sensitivity and expertise they deserve. Our solutions are grounded in rigorous research, designed for patient comfort, and supported by comprehensive education.
We don’t just treat symptoms. We help you reclaim your ability to truly feel.
This is The Art of Feeling.
References
- 1 / Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010 Jan;85(1):87-94. doi: 10.4065/mcp.2009.0413.
- 2 / Nasreen SZA, et al. American Journal of Internal Medicine. 2019;7(6):154-62.
- 3 / Benini V, et al. Medicina (Kaunas). 2022;58(6):770
- 4 / Christmas M, et al. Clin Obstet Gynecol. 2024;67(1):101-14.
- 5 / Palacios S, Nappi RE, Bruyniks N, Particco M, Panay N; EVES Study Investigators. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric. 2018 Jun;21(3):286-291. doi: 10.1080/13697137.2018.1446930. Epub 2018 Mar 19.

